• Neurocrine Inks $50M Xenon Pharma Deal to Expand Into Epilepsy

    8 days ago - By Xconomy

    Neurocrine Biosciences is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder. The Xenon deal is the second one San Diego-based Neurocrine has struck this year in a bid to expand the landscape of neurological disorders for which it can offer treatment. For its $50 million, Neurocrine gets the rights to Xenon's experimental treatment for a rare, hereditary form of early-onset epilepsy caused by mutations to the gene SCN8A...
    Read more ...